Jade Biosciences, Inc. Common Stock JBIO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.15M+68.1% | $93.12M+43.3% | $95.81M+85.9% | $87.39M+59.3% | $64.92M-8.3% | ||
| $24.45M+156% | $20.42M+90.2% | $18.29M+71.1% | $14.28M+3.6% | $9.56M-45.6% | ||
| $133.6M+79.4% | $113.54M+50.0% | $114.1M+83.3% | $101.67M+48.1% | $74.48M-15.7% | ||
| -$133.6M-79.4% | -$113.54M-50.0% | -$114.1M-83.3% | -$101.67M-48.1% | -$74.48M+15.7% | ||
| —— | —— | -$28.36M-1,650% | -$31.89M-745% | -$27.54M-540% | ||
| —— | —— | —— | —— | —— | ||
| $59.5K— | $58K— | $43.5K— | —— | —— | ||
| -$129.61M-27.0% | -$127.41M-46.4% | -$142.46M-136% | -$133.56M-109% | -$102.02M-24.1% | ||
| -$2.02+93.8% | -$13.55+35.7% | -$28.33-309% | -$33.01-1,236% | -$32.34-964% | ||
| -$133.57M-80.0% | -$113.52M-50.5% | -$114.08M-84.2% | -$101.43M-48.0% | -$74.22M+15.9% | ||
| -$133.6M-79.4% | -$113.54M-50.0% | -$114.1M-83.3% | -$101.67M-48.1% | -$74.48M+15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Jade Biosciences, Inc. Common Stock profitable?
- Jade Biosciences, Inc. Common Stock is not currently profitable: it reported a net loss of $129.6M over the trailing twelve months.
- What is Jade Biosciences, Inc. Common Stock's earnings per share?
- Jade Biosciences, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.02.
- Where does Jade Biosciences, Inc. Common Stock's income statement data come from?
- Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.